卡瑞利珠单抗联合白蛋白紫杉醇+铂类化疗治疗局部晚期食管癌患者的临床疗效  

Clinical efficacy of camrelizumab combined with albumin-bound paclitaxel and platinum-based chemotherapy in patients with locally advanced esophageal cancer

作　　者：揭永波 朱兴平 JIE Yongbo;ZHU Xingping(Department of Medical Oncology,Shangrao Dongxin Fifth Hospital,Shangrao 334000,Jiangxi,China)

机构地区：[1]上饶东信第五医院肿瘤内科,江西上饶334000

出　　处：《癌症进展》2025年第8期963-966,共4页Oncology Progress

摘　　要：目的目的探讨卡瑞利珠单抗联合白蛋白紫杉醇^(+)铂类化疗治疗局部晚期食管癌患者的临床疗效。方法方法根据治疗方法的不同将80例局部晚期食管癌患者分为对照组(n=40,白蛋白紫杉醇^(+)铂类化疗)和观察组(n=40,卡瑞利珠单抗联合白蛋白紫杉醇^(+)铂类化疗)。比较两组患者的临床疗效、T淋巴细胞亚群(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肿瘤标志物[癌胚抗原(CEA)、鳞状细胞癌抗原(SCC-Ag)、糖类抗原125(CA125)]水平及不良反应发生情况。结果观察组患者的总有效率为55.00%,高于对照组患者的32.50%,差异有统计学意义(P﹤0.05)。治疗后,观察组患者CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)、CEA、SCC-Ag、CA125水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者毛细血管增生症、肝功能损伤、胃肠道反应、骨髓抑制发生率比较,差异均无统计学意义(P﹥0.05)。结论结论卡瑞利珠单抗联合白蛋白紫杉醇^(+)铂类化疗治疗局部晚期食管癌患者可提高临床疗效,降低免疫损伤及肿瘤标志物水平,且未明显增加不良反应。Objective To explore the clinical efficacy of camrelizumab combined with albumin-bound paclitaxel and platinum-based chemotherapy in patients with locally advanced esophageal cancer.Method According to different treat-ment methods,80 patients with locally advanced esophageal cancer were divided into control group(n=40,albumin-bound paclitaxel^(+)platinum-based chemotherapy)and observation group(n=40,camrelizumab combined with albumin-bound paclitaxel^(+)platinum-based chemotherapy).The clinical efficacy,T lymphocyte subsets(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),tu-mor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),carbohydrate antigen 125(CA125)]levels and adverse reactions were compared between the two groups.Result The total effective rate of obser-vation group was 55.00%,higher than 32.50%of control group,the difference was statistically significant(P<0.05).After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in observation group were higher than those in control group,the levels of CD8^(+),CEA,SCC-Ag and CA125 were lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidences of capillary hyperplasia,liver function injury,gastrointesti-nal reaction and bone marrow suppression between the two groups(P>0.05).Conclusion Camrelizumab combined with albumin-bound paclitaxel and platinum-based chemotherapy in the treatment of locally advanced esophageal cancer can improve clinical efficacy,reduce immune damage and tumor marker levels,and does not significantly increase adverse re-actions.

关 键 词：晚期食管癌 卡瑞利珠单抗 白蛋白紫杉醇 铂类 临床疗效 不良反应 

分 类 号：R735.1[医药卫生—肿瘤]